EVMN — EVOMMUNE INC
As of Q2 2026, 22 SEC-registered investment managers reported holding EVMN (EVOMMUNE INC) in their latest 13F filings, with a combined reported value of $84.14M across 8.06M shares. That is +76.1% by share count (+3.49M shares) versus the previous quarter, while reported value moved +5.7%. Ownership is concentrated: the five largest holders account for 80.9% of reported value and the top ten for 97.0%.
Compared with the prior quarter, 6 opened new positions, 14 added to existing stakes, 2 trimmed, 2 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
EVMN is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
| Fund | Quarter | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|---|
| JPMorgan Chase & Co history | Q2 2026 | 1.55M | $23.37M | 0.00% | New |
| Janus Henderson Group history | Q1 2026 | 896.70K | $20.62M | 0.01% | New |
| Marshall Wace history | Q1 2026 | 879.73K | $20.22M | 0.02% | Reduce |
| Point72 Asset Management history | Q2 2026 | 1.44M | $19.07M | 0.02% | Add |
| BlackRock Inc history | Q2 2026 | 886.54K | $11.78M | 0.00% | Add |
| Vanguard Group history | Q4 2025 | 502.57K | $8.60M | 0.00% | New |
| Balyasny Asset Management history | Q2 2026 | 627.01K | $8.33M | 0.01% | New |
| UBS Group AG history | Q2 2026 | 413.55K | $5.50M | 0.00% | Add |
| Geode Capital Management history | Q2 2026 | 301.76K | $4.01M | 0.00% | Add |
| Morgan Stanley history | Q2 2026 | 290.17K | $3.86M | 0.00% | Add |
| Goldman Sachs Group history | Q2 2026 | 193.00K | $2.56M | 0.00% | Add |
| Charles Schwab Investment Management history | Q2 2026 | 133.07K | $1.77M | 0.00% | Add |
| Northern Trust Corp history | Q2 2026 | 101.40K | $1.35M | 0.00% | Add |
| Citadel Advisors history | Q2 2026 | 47.92K | $636.91K | 0.00% | New |
| Manulife Financial history | Q2 2026 | 38.91K | $517.09K | 0.00% | Add |
| BNY Mellon history | Q2 2026 | 25.55K | $339.57K | 0.00% | Add |
| Two Sigma Investments history | Q2 2026 | 25.53K | $339.24K | 0.00% | New |
| Deutsche Bank AG history | Q2 2026 | 12.61K | $167.60K | 0.00% | New |
| Wells Fargo & Co history | Q2 2026 | 12.07K | $160.36K | 0.00% | Add |
| Bank of America Corp history | Q2 2026 | 10.87K | $144.44K | 0.00% | Reduce |
New Positions (Q2 2026)
- JPMorgan Chase & Co 1.55M sh · $23.37M
- Balyasny Asset Management 627.01K sh · $8.33M
- Citadel Advisors 47.92K sh · $636.91K
- Two Sigma Investments 25.53K sh · $339.24K
- Deutsche Bank AG 12.61K sh · $167.60K
- PNC Financial Services 92 sh · $1.22K
Fully Exited (vs previous quarter)
- Janus Henderson Group sold 896.70K sh · $20.62M
- Marshall Wace sold 879.73K sh · $20.22M
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|
| JPMorgan Chase & Co | 1.31M | — | 1.55M |
| Point72 Asset Management | 34.38K | 36.58K | 1.44M |
| BlackRock Inc | 142.44K | 673.57K | 886.54K |
| Balyasny Asset Management | 65.00K | — | 627.01K |
| UBS Group AG | 3.41K | 298.38K | 413.55K |
| Geode Capital Management | 109.78K | 248.61K | 301.76K |
| Morgan Stanley | 8.35K | 25.07K | 290.17K |
| Goldman Sachs Group | 61.67K | 154.32K | 193.00K |
| Charles Schwab Investment Management | 62.70K | 94.95K | 133.07K |
| Northern Trust Corp | 22.64K | 79.75K | 101.40K |
| Citadel Advisors | 50.56K | — | 47.92K |
| Manulife Financial | 10.22K | 12.81K | 38.91K |
| BNY Mellon | — | 22.09K | 25.55K |
| Two Sigma Investments | 21.32K | — | 25.53K |
| Deutsche Bank AG | — | — | 12.61K |
| Wells Fargo & Co | — | 3.87K | 12.07K |
| Bank of America Corp | 2.94K | 30.20K | 10.87K |
| Legal & General Investment Management America | 400 | 919 | 8.52K |
| Citigroup Inc | — | 518 | 6.25K |
| T. Rowe Price Associates | 782.12K | 1.12M | 1.94M |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details